Payment overview · 2025
General Payments
$635.88
30 reported records · 15 companies
Healthcare provider profile · identity verified
Nicholas Gary Hanson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SLC, UT · NPI 1710149794
Verified facts
What the public records show
CMS Open Payments records show Nicholas Gary Hanson, M.D. received $635.88 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.29 | 21.6% | 7 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $107.81 | 16.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.11 | 8.8% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $43.91 | 6.9% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $40.44 | 6.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.37 | 5.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $36.59 | 5.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.98 | 5.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.38 | 4.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.95 | 3.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $21.72 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.91 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.72 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.56 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $635.88 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $107.81 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $66.73 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.11 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $43.91 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $40.44 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 48 |
| Lisinopril | Lisinopril | 159 | 42 |
| Omeprazole | Omeprazole | 137 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 128 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 23 |
| Losartan Potassium | Losartan Potassium | 106 | 31 |
| Gabapentin | Gabapentin | 104 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 30 |
| Trazodone Hcl | Trazodone Hcl | 91 | 20 |
| Meloxicam | Meloxicam | 89 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 21 |
| Metformin Hcl Er | Metformin Hcl | 82 | 24 |
| Metformin Hcl | Metformin Hcl | 80 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 22 |
| Alprazolam | Alprazolam | 76 | 16 |
| Eliquis | Apixaban | 74 | 16 |
| Alendronate Sodium | Alendronate Sodium | 73 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 12 |
| Simvastatin | Simvastatin | 65 | 20 |
| Mounjaro | Tirzepatide | 60 | 14 |
| Myrbetriq | Mirabegron | 59 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Finasteride | Finasteride | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Potassium Chloride | Potassium Chloride | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 11 |
| Ibuprofen | Ibuprofen | 42 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Furosemide | Furosemide | 40 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 14 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 12 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Fluconazole | Fluconazole | 28 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Azithromycin | Azithromycin | 21 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $635.88 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FARXIGA, GARDASIL 9, Hillrom - Vest System Model 105 Home Care, Kerendia, NEUROSTAR TMS THERAPY SYSTEM, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error